Targets › HIF2A
3 programs from 3 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Nov 2026.
Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). (UniProt, Q99814)
Open in Phaseline: the race on HIF2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | MK-3795 HIF-2α inhibitor | HIF2A | Phase 1 | ccRCC | Nov 2026 |
| Jiangsu Hansoh Pharmaceutical | HS-10516 HIF-2α inhibitor | HIF2A | Phase 1 | Advanced Clear Cell Renal Cell Carcinoma; Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma | Jul 2027 |
| Orhan Kemal Oz | [18F]PT2385 HIF2α PET imaging agent | HIF2A | Phase 1 | Renal Cell Carcinoma | Aug 2027 |
Renal Cell Carcinoma (1) Advanced Clear Cell Renal Cell Carcinoma (1) Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma (1) ccRCC (1)
small molecule (2), mixed (1)
Orhan Kemal Oz (1) Jiangsu Hansoh Pharmaceutical (1) Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.